Osteoclasts control reactivation of dormant myeloma cells by remodelling the endosteal niche

Nature Communications

Volumn 6, Issue , 2015, Pages

  Lawson, Michelle A ^a   McDonald, Michelle M ^b,c   Kovacic, Natasa ^b   Khoo, Weng Hua ^b,c   Terry, Rachael L ^b,c   Down, Jenny ^b   Kaplan, Warren ^b,c   Paton Hough, Julia ^a   Fellows, Clair ^a   Pettitt, Jessica A ^b   Dear, T Neil ^d   Van Valckenborgh, Els ^e   Baldock, Paul A ^b,c   Rogers, Michael J ^b,c   Eaton, Colby L ^a   Vanderkerken, Karin ^e   Pettit, Allison R ^f   Quinn, Julian M W ^b   Zannettino, Andrew C W ^d,g   Phan, Tri Giang ^b,c   Croucher, Peter I ^b,c   more..

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d SOUTH AUSTRALIAN HEALTH AND MEDICAL RESEARCH INSTITUTE   (Australia)

^e VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^f UNIVERSITY OF QUEENSLAND   (Australia)

^g UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 MICROGLOBULIN; CARBOXY TERMINAL TELOPEPTIDE; MELPHALAN; OSTEOCLAST DIFFERENTIATION FACTOR; SYNDECAN 1; VASCULAR CELL ADHESION MOLECULE 1;

CELLS AND CELL COMPONENTS; CHEMOTHERAPY; DISEASE; DORMANCY; DRUG RESISTANCE; IMAGING METHOD; REACTIVATION; TUMOR;

ADULT; AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DIVISION; CELL GROWTH; CELL LINEAGE; CELL PROLIFERATION; CELL SUBPOPULATION; CONTROLLED STUDY; FEMALE; HUMAN; IN VITRO STUDY; LIPOPHILICITY; MAJOR CLINICAL STUDY; MALE; MICROENVIRONMENT; MOUSE; MULTIPLE MYELOMA; MYELOMA CELL; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOCLAST ACTIVITY; OSTEOCLASTOGENESIS; OSTEOLYSIS; PROMOTER REGION; STEM CELL NICHE; TRABECULAR BONE; TUMOR VOLUME; ANIMAL; BONE REMODELING; COCULTURE; INBRED MOUSE STRAIN; METABOLISM; MIDDLE AGED; PHYSIOLOGY; TUMOR CELL LINE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANIMALS; BONE REMODELING; CELL LINE, TUMOR; COCULTURE TECHNIQUES; FEMALE; HUMANS; MALE; MICE; MICE, INBRED STRAINS; MIDDLE AGED; MULTIPLE MYELOMA; OSTEOBLASTS; OSTEOCLASTS;

EID: 84949257661     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms9983     Document Type: Article

References (66)

1. Aguirre-Ghiso, J. A. Models, mechanisms and clinical evidence for cancer dormancy. Nat. Rev. Cancer 7, 834-846 (2007).
2. Goss, P. E. & Chambers, A. F. Does tumour dormancy offer a therapeutic target? Nat. Rev. Cancer 10, 871-877 (2010).
3. Schardt, J. A. et al. Genomic analysis of single cytokeratin-positive cells from bone marrow reveals early mutational events in breast cancer. Cancer Cell 8, 227-239 (2005).
4. Chambers, A. F., Groom, A. C. & MacDonald, I. C. Dissemination and growth of cancer cells in metastatic sites. Nat. Rev. Cancer 2, 563-572 (2002).
5. San Miguel, J. F. et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N. Engl. J. Med. 359, 906-917 (2008).
6. Morgan, G. J., Walker, B. A. & Davies, F. E. The genetic architecture of multiple myeloma. Nat. Rev. Cancer 12, 335-348 (2012).
7. Bolli, N. et al. Heterogeneity of genomic evolution and mutational profiles in multiple myeloma. Nat. Commun. 5, 2997 (2014).
8. Egan, J. B. et al. Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides. Blood 120, 1060-1066 (2012).
9. Keats, J. J. et al. Clonal competition with alternating dominance in multiple myeloma. Blood 120, 1067-1076 (2012).
10. Melchor, L. et al. Single-cell genetic analysis reveals the composition of initiating clones and phylogenetic patterns of branching and parallel evolution in myeloma. Leukemias 28, 1705-1715 (2014).
11. Chen, Z., Orlowski, R. Z., Wang, M., Kwak, L. & McCarty, N. Osteoblastic niche supports the growth of quiescent multiple myeloma cells. Blood 123, 2204-2208 (2014).
12. Ding, L., Saunders, T. L., Enikolopov, G. & Morrison, S. J. Endothelial and perivascular cells maintain haematopoietic stem cells. Nature 481, 457-462 (2012).
13. Kollet, O. et al. Osteoclasts degrade endosteal components and promote mobilization of hematopoietic progenitor cells. Nat. Med. 12, 657-664 (2006).
14. Calvi, L. M. et al. Osteoblastic cells regulate the haematopoietic stem cell niche. Nature 425, 841-846 (2003).
15. Mansour, A. et al. Osteoclasts promote the formation of hematopoietic stem cell niches in the bone marrow. J. Exp. Med. 209, 537-549 (2012).
16. Visnjic, D. et al. Hamatopoiesis is severely altered in mice with an induced osteoblast deficiency. Blood 103, 3258-3264 (2004).
17. Zhang, J. et al. Identification of the haematopoietic stem cell niche and control of the niche size. Nature 425, 836-841 (2003).
18. Sacchetti, B. et al. Self-renewing osteoprogenitors in bone marrow sinusoids can organize a hematopoietic microenvironment. Cell 131, 324-336 (2007).
19. Boyd, A. L. et al. Niche displacement of human leukemic stem cells uniquely allows their competitive replacement with healthy HSPCs. J. Exp. Med. 211, 1925-1935 (2014).
20. Sipkins, D. A. et al. In vivo imaging of specialized bone marrow endothelial microdomains for tumour engraftment. Nature 435, 969-973 (2005).
21. Shiozawa, Y. et al. Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow. J. Clin. Invest. 121, 1298-1312 (2011).
22. Mazo, I. B. et al. Hematopoietic progenitor cell rolling in bone marrow microvessels: parallel contributions by endothelial selectins and vascular cell adhesion molecule 1. J. Exp. Med. 188, 465-474 (1998).
23. Junt, T. et al. Dynamic visualization of thrombopoiesis within bone marrow. Science 317, 1767-1770 (2007).
24. Lo Celso, C. et al. Live-animal tracking of individual haematopoietic stem/progenitor cells in their niche. Nature 457, 92-96 (2009).
25. Lo Celso, C., Lin, C. P. & Scadden, D. T. In vivo imaging of transplanted hematopoietic stem and progenitor cells in mouse calvarium bone marrow. Nat. Protoc. 6, 1-14 (2011).
26. Adams, G. B. et al. Haematopoietic stem cells depend on Galpha(s)-mediated signalling to engraft bone marrow. Nature 459, 103-107 (2009).
27. Fujisaki, J. et al. In vivo imaging of Treg cells providing immune privilege to the haematopoietic stem-cell niche. Nature 474, 216-219 (2011).
28. Roccaro, A. M. et al. BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression. J. Clin. Invest. 123, 1542-1555 (2013).
29. Foudi, A. et al. Analysis of histone 2B-GFP retention reveals slowly cycling hematopoietic stem cells. Nat. Biotechnol. 27, 84-90 (2009).
30. Wilson, A. et al. Hematopoietic stem cells reversibly switch from dormancy to self-renewal during homeostasis and repair. Cell 135, 1118-1129 (2008).
31. Tumbar, T. et al. Defining the epithelial stem cell niche in skin. Science 303, 359-363 (2004).
32. Szotek, P. P. et al. Normal ovarian surface epithelial label-retaining cells exhibit stem/progenitor cell characteristics. Proc. Natl Acad. Sci. USA 105, 12469-12473 (2008).
33. Lassailly, F., Griessinger, E. & Bonnet, D. "Microenvironmental contaminations" induced by fluorescent lipophilic dyes used for noninvasive in vitro and in vivo cell tracking. Blood 115, 5347-5354 (2010).
34. Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545-15550 (2005).
35. Bidwell, B. N. et al. Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape. Nat. Med. 18, 1224-1231 (2012).
36. Lu, X. et al. VCAM-1 promotes osteolytic expansion of indolent bone micrometastasis of breast cancer by engaging alpha4beta1-positive osteoclast progenitors. Cancer cell 20, 701-714 (2011).
37. Taichman, R. S. et al. GAS6 receptor status is associated with dormancy and bone metastatic tumor formation. PLoS ONE 8, e61873 (2013).
38. Kalajzic, I. et al. Use of type I collagen green fluorescent protein transgenes to identify subpopulations of cells at different stages of the osteoblast lineage. J. Bone Miner. Res. 17, 15-25 (2002).
39. Boyle, W. J., Simonet, W. S. & Lacey, D. L. Osteoclast differentiation and activation. Nature 423, 337-342 (2003).
40. Ninomiya, M. et al. Homing, proliferation and survival sites of human leukemia cells in vivo in immunodeficient mice. Leukemia 21, 136-142 (2007).
41. Rosen, J. M. & Jordan, C. T. The increasing complexity of the cancer stem cell paradigm. Science 324, 1670-1673 (2009).
42. Van Valckenborgh, E. et al. Tumor-initiating capacity of CD138-and CD138+ tumor cells in the 5T33 multiple myeloma model. Leukemia 26, 1436-1439 (2012).
43. Matsui, W. et al. Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance. Cancer Res. 68, 190-197 (2008).
44. Yaccoby, S. et al. Inhibitory effects of osteoblasts and increased bone formation on myeloma in novel culture systems and a myelomatous mouse model. Haematologica 91, 192-199 (2006).
45. Li, X., Ling, W., Khan, S. & Yaccoby, S. Therapeutic effects of intrabone and systemic mesenchymal stem cell cytotherapy on myeloma bone disease and tumor growth. J. Bone Miner. Res. 27, 1635-1648 (2012).
46. Ro, T. B. et al. Bone morphogenetic protein-5,-6 and-7 inhibit growth and induce apoptosis in human myeloma cells. Oncogene 23, 3024-3032 (2004).
47. Tan, S. H. et al. Wnts produced by Osterix-expressing osteolineage cells regulate their proliferation and differentiation. Proc. Natl Acad. Sci. USA 111, E5262-E5271 (2014).
48. Dosen, G. et al. Wnt expression and canonical Wnt signaling in human bone marrow B lymphopoiesis. BMC Immunol. 7, 13 (2006).
49. Croucher, P. I. et al. Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma. Blood 98, 3534-3540 (2001).
50. Croucher, P. I. et al. Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival. J. Bone Miner. Res. 18, 482-492 (2003).
51. Vanderkerken, K., Asosingh, K., Van Camp, B. & Croucher, P. Anti-tumor effect of recombinant OPG in the murine 5T33MM model. Blood 98, 637a (2001).
52. Morgan, G. J. et al. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. Lancet 376, 1989-1999 (2010).
53. Bataille, R., Chappard, D. & Basle, M. Quantifiable excess of bone resorption in monoclonal gammopathy is an early sympton of malignancy: a prospective study of 87 bone biospies. Blood 87, 4762-4769 (1996).
54. Vanderkerken, K. et al. Organ involvement and phenotypic adhesion profile of 5T2 and 5T33MM cells in the C57BL/KaLwRij mouse. Br. J. Cancer 76, 451-460 (1997).
55. Oyajobi, B. O. et al. Detection of myeloma in skeleton of mice by whole-body optical fluorescence imaging. Mol. Cancer Ther. 6, 1701-1708 (2007).
56. Riedel, S. S. et al. Non-invasive imaging provides spatiotemporal information on disease progression and response to therapy in a murine model of multiple myeloma. PLoS ONE 7, e52398 (2012).
57. Sudo, H., Kodama, H. A., Amagai, Y., Yamamoto, S. & Kasai, S. In vitro differentiation and calcificatio n in a new clonal osteogenic cell line derived from newborn mouse calvaria. J. Cell Biol. 96, 191-198 (1983).
58. Bakker, A. & Klein-Nulend, J. Osteoblast isolation from murine calvariae and long bones. Methods Mol. Med. 80, 19-28 (2003).
59. Chtanova, T. et al. Real-time interactive two-photon photoconversion of recirculating lymphocytes for discontinuous cell tracking in live adult mice. J. Biophotonics 123, 2204-2208 (2012).
60. Nair, R. et al. c-Myc and Her2 cooperate to drive a stem-like phenotype with poor prognosis in breast cancer. Oncogene 33, 3992-4002 (2013).
61. Leek, J. T. & Storey, J. D. Capturing heterogeneity in gene expression studies by surrogate variable analysis. PLoS Genet. 3, 1724-1735 (2007).
62. Augustine, C. K. et al. Gene expression signatures as a guide to treatment strategies for in-transit metastatic melanoma. Mol. Cancer Ther. 9, 779-790 (2010).
63. Boegsted, M. et al. Generation of a predictive melphalan resistance index by drug screen of B-cell cancer cell lines. PLoS ONE 6, e19322 (2011).
64. Huang, da, W., Sherman, B. T. & Lempicki, R. A. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 4, 44-57 (2009).
65. Huang, da, W., Sherman, B. T. & Lempicki, R. A. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res. 37, 1-13 (2009).
66. Reich, M. et al. GenePattern 2.0. Nat. Genet. 38, 500-501 (2006).